GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Phibro Animal Health Corp (NAS:PAHC) » Definitions » Altman Z2-Score

Phibro Animal Health (Phibro Animal Health) Altman Z2-Score : 4.25 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Phibro Animal Health Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Phibro Animal Health has a Altman Z2-Score of 4.25, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Phibro Animal Health's Altman Z2-Score or its related term are showing as below:

PAHC' s Altman Z2-Score Range Over the Past 10 Years
Min: 2.52   Med: 4.41   Max: 5.12
Current: 4.25

During the past 13 years, Phibro Animal Health's highest Altman Z2-Score was 5.12. The lowest was 2.52. And the median was 4.41.


Phibro Animal Health Altman Z2-Score Historical Data

The historical data trend for Phibro Animal Health's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phibro Animal Health Altman Z2-Score Chart

Phibro Animal Health Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.81 4.15 4.50 4.53 4.57

Phibro Animal Health Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.57 4.55 4.57 4.45 4.25

Competitive Comparison of Phibro Animal Health's Altman Z2-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phibro Animal Health's Altman Z2-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Phibro Animal Health's Altman Z2-Score falls into.



Phibro Animal Health Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Phibro Animal Health's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.41+3.26*0.2513+6.72*0.0502+1.05*0.3858
=4.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $972.7 Mil.
Total Current Assets was $586.6 Mil.
Total Current Liabilities was $187.7 Mil.
Retained Earnings was $244.5 Mil.
Pre-Tax Income was 3.565 + -11.979 + 21.441 + 15.104 = $28.1 Mil.
Interest Expense was -5.41 + -5.317 + -5.234 + -4.718 = $-20.7 Mil.
Total Liabilities was $701.9 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(586.586 - 187.735)/972.708
=0.41

X2=Retained Earnings/Total Assets
=244.45/972.708
=0.2513

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(28.131 - -20.679)/972.708
=0.0502

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(270.803 - 0)/701.905
=0.3858

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Phibro Animal Health has a Altman Z2-Score of 4.25 indicating it is in Safe Zones.


Phibro Animal Health  (NAS:PAHC) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Phibro Animal Health Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Phibro Animal Health's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Phibro Animal Health (Phibro Animal Health) Business Description

Traded in Other Exchanges
Address
300 Frank W. Burr Boulevard, Suite 21, 3rd Floor, Glenpointe Centre East, Teaneck, NJ, USA, 07666-6712
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Executives
Judith Weinstein officer: See Remarks C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666
Alejandro Bernal director C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
E Thomas Corcoran director
Larry Lee Miller officer: Chief Operating Officer 8 HAZELWOOD COURT, WARREN NJ 07059
Damian Finio officer: Chief Financial Officer C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310
Robin Aukerman officer: President,North America Region C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666
Daniel M Bendheim director, officer: Exec. VP, Corporate Strategy 300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666
Dean J Warras officer: Pres Animal Health & Nutr N.A. 5113 SPYGLASS HILL, QUINCY IL 62305
Jack Bendheim director, 10 percent owner, officer: President and CEO C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024
Bfi Co., Llc 10 percent owner 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Jonathan Bendheim director GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666
Anthony Andolino officer: SEE REMARKS GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666
Richard G Johnson officer: Chief Financial Officer 7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025
Gerald K Carlson director 2496 OLD BEACH ROAD, WAYZATA MN 55391
Thomas G Dagger officer: SVP, Gen Counsel and Corp Sec 41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046